硝苯地平介导药物性牙龈增生的研究进展  

Research advance of Nifedipine induced gingival hyperplasia

作　　者：文海燕[1] 束蓉[1] 

机构地区：[1]上海交通大学医学院附属第九人民医院牙周病科,上海200011

出　　处：《国际口腔医学杂志》2009年第1期84-87,共4页International Journal of Stomatology

基　　金："十一五"国家科技支撑计划基金资助项目(2007BAI-18B02)

摘　　要：药物性牙龈增生(DGO)是临床常见性牙周疾病。硝苯地平(NIF)为第1代钙离子拮抗剂,其副作用可引发DGO。在NIF介导的DGO中,与程序性细胞死亡相关的调节基因B细胞淋巴瘤/白血病-2基因和c-myc以及转录因子叉头框蛋白在抑制细胞程序性死亡的过程中起重要作用。成纤维细胞表面所表达的补体受体具有异质性,与DGO的发生密切相关。炎症因子和黏附分子对DGO的作用也不可忽视。下文就近年来NIF介导DGO的国内外相关研究进展作一综述。Drug-induced gingival hyperplasia is a common periodontal disease in the clinic. Nifedipine is the first generation of the calcium channel blockers. Drug-induced gingival hyperplasia is one side effect of the Nifedipine. In the Nifedipine induced gingival hyperplasia, apoptosis-related regulator gene B cell lymphoma/leukmia （hcl）-2, c-mye, and transcription factor forkhead box （Fox） all play important roles in the process of inhibiting cell apoptosis. The heterogeneity of fibroblast expressed complement receptors is related to the mechanism of the drug-in- duced gingival hyperplasia. The role of inflammatory cytokines and adhesion molecules in drug-induced gingival hyperplasia should not be overlooked. This article will review the latest researches on the nifedipine induced gingival hyperplasia.

关 键 词：药物性牙龈过度增生 硝苯地平 B细胞淋巴瘤/白血病-2 叉头框蛋白 转化生长因子-Β 

分 类 号：R781.4[医药卫生—口腔医学]